Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy

A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probene...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Evan C., Rubinstein, Jack, Strande, Jennifer L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301499/
https://www.ncbi.nlm.nih.gov/pubmed/34316787
http://dx.doi.org/10.1016/j.jaccas.2019.07.008
_version_ 1783726683989213184
author Klein, Evan C.
Rubinstein, Jack
Strande, Jennifer L.
author_facet Klein, Evan C.
Rubinstein, Jack
Strande, Jennifer L.
author_sort Klein, Evan C.
collection PubMed
description A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probenecid therapy, which allowed for successful elimination of his intravenous therapies. (Level of Difficulty: Intermediate.)
format Online
Article
Text
id pubmed-8301499
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83014992021-07-26 Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy Klein, Evan C. Rubinstein, Jack Strande, Jennifer L. JACC Case Rep Case Report A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral probenecid therapy, which allowed for successful elimination of his intravenous therapies. (Level of Difficulty: Intermediate.) Elsevier 2019-08-21 /pmc/articles/PMC8301499/ /pubmed/34316787 http://dx.doi.org/10.1016/j.jaccas.2019.07.008 Text en © 2019 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Klein, Evan C.
Rubinstein, Jack
Strande, Jennifer L.
Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
title Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
title_full Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
title_fullStr Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
title_full_unstemmed Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
title_short Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
title_sort probenecid: an oral inotrope for end-stage heart failure in a case with myotonic dystrophy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301499/
https://www.ncbi.nlm.nih.gov/pubmed/34316787
http://dx.doi.org/10.1016/j.jaccas.2019.07.008
work_keys_str_mv AT kleinevanc probenecidanoralinotropeforendstageheartfailureinacasewithmyotonicdystrophy
AT rubinsteinjack probenecidanoralinotropeforendstageheartfailureinacasewithmyotonicdystrophy
AT strandejenniferl probenecidanoralinotropeforendstageheartfailureinacasewithmyotonicdystrophy

Ejemplares similares